title: Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis.
abstract: BACKGROUND
  Systemic mastocytosis is a clonal myeloproliferative neoplasm associated with constitutional symptoms from mast cell mediated chemical and cytokine release. According to the literature, Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to reduce symptoms related to proinflammatory cytokine release in other myeloproliferative neoplasms.
  
  
  METHODS
  Here we present a case using Ruxolitinib for disabling constitutional symptoms despite complete bone marrow response in a patient with aggressive systemic mastocytosis. Assessment tools used to monitor symptoms in previously published Ruxolitinib trials were adopted to track symptom improvement and quality of life.
  
  
  CONCLUSIONS
  Ruxolitinib significantly improved symptoms and quality of life in our patient with systemic mastocytosis.
authors: Division of Hematology and Oncology, Univerity of Kansas Medical Center, 2330 Shawnee Mission Parkway, 66205 Westwood, Kansas USA.
authors: Abdulraheem
authors: A
authors: Yacoub
authors: Division of Hematology and Oncology, Univerity of Kansas Medical Center, 2330 Shawnee Mission Parkway, 66205 Westwood, Kansas USA.
authors: Lindsey
authors: L
authors: Prochaska
keywords: Mastocytosis; Quality of life; Ruxolitinib; Systemic mastocytosis